Summary
Only thyroid C-cell tumor risk/monitoring and related contraindications are supported by the provided FDA label excerpt; most other clinical program, dosing, outcomes, safety endpoint, and comparative trial claims are not supported by the supplied prescribing information sections.
Category Scores
Accurate Statements
Trial programs monitor thyroid C-cell tumor signals.
Label 5.1 describes thyroid C-cell tumor risk and includes counseling and evaluation/possible measurement of calcitonin; it also references symptoms and evaluation when calcitonin is elevated or nodules are present.
Trial programs monitor other serious adverse events.
Label 6 lists serious adverse reaction(s) (including thyroid C-cell tumors) described below or elsewhere in the prescribing information; the excerpt supports that serious adverse reactions are described/managed, but does not specify what other events trial programs monitor.
Claim: Ozempic is semaglutide.
The provided FDA label excerpt refers to OZEMPIC as semaglutide (e.g., 5.1 discusses semaglutide; 4 contraindications reference semaglutide; 17 patient counseling references semaglutide).
Claim: Semaglutide is a GLP-1 receptor agonist.
Label 5.1 mentions liraglutide as another GLP-1 receptor agonist and discusses semaglutide in that context.
Unsupported Statements
The clinical evidence most often cited for Ozempic comes from the Phase 3 STEP program for weight management.
No labeling excerpt provided includes STEP/Phase 3 program descriptions for OZEMPIC.
The clinical evidence most often cited for Ozempic comes from the Phase 3 SUSTAIN program for type 2 diabetes.
No labeling excerpt provided includes SUSTAIN/Phase 3 program descriptions for OZEMPIC.
The Phase 3 trials SUSTAIN studies tested semaglutide against comparators including placebo and/or other diabetes treatments to evaluate effects on blood sugar control and safety.
No labeling excerpt provided includes details of trial comparators, endpoints, or design for SUSTAIN.
The STEP trials evaluated semaglutide 2.4 mg.
No labeling excerpt provided includes STEP trials or semaglutide 2.4 mg evaluation details.
Semaglutide 2.4 mg is marketed as Wegovy.
The provided FDA label excerpt for OZEMPIC does not mention Wegovy or semaglutide 2.4 mg marketing.
In type 2 diabetes studies of semaglutide, common endpoints included changes in A1c.
No labeling excerpt provided includes A1c endpoint statements.
In type 2 diabetes studies of semaglutide, common endpoints included proportions of participants reaching glycemic targets.
No labeling excerpt provided includes glycemic target responder endpoint statements.
In type 2 diabetes studies of semaglutide, safety outcomes typically included hypoglycemia events.
No labeling excerpt provided includes hypoglycemia safety endpoint statements.
In type 2 diabetes studies of semaglutide, safety outcomes typically included gastrointestinal side effects.
No labeling excerpt provided includes gastrointestinal adverse event frequency/typical safety outcomes.
In semaglutide weight-management studies, endpoints typically included weight loss both in absolute terms and percent change from baseline.
No labeling excerpt provided includes weight-management endpoints.
In semaglutide weight-management studies, endpoints included safety tolerability.
No labeling excerpt provided includes weight-management safety/tolerability endpoint statements.
In semaglutide weight-management studies, gastrointestinal effects were among the most frequent.
No labeling excerpt provided includes frequency ranking of gastrointestinal effects.
Ozempic and Wegovy overlap scientifically because they use the same drug class and the same drug molecule (semaglutide).
The provided FDA label excerpt does not mention Wegovy; while semaglutide is a GLP-1 receptor agonist in 5.1 context, the excerpt does not support the Wegovy-specific comparison statement.
Ozempic and Wegovy differ mainly by indication and the dose used in trials.
The provided FDA label excerpt does not mention Wegovy or dose/indication differences.
The weight-management dataset most associated with semaglutide at higher doses (STEP program for Wegovy) is distinct from the type 2 diabetes dataset used for Ozempic (SUSTAIN program).
No labeling excerpt provided includes STEP/Wegovy versus SUSTAIN/Ozempic dataset distinctions.
Semaglutide has cardiovascular outcomes evidence in people with type 2 diabetes at high cardiovascular risk.
No labeling excerpt provided includes cardiovascular outcomes evidence.
The cardiovascular outcomes evidence for semaglutide comes from a dedicated outcomes study rather than only glucose-control Phase 3 trials.
No labeling excerpt provided includes details of cardiovascular outcomes study design.
Across semaglutide trials, the most frequently reported adverse effects involve the gastrointestinal tract.
No labeling excerpt provided includes cross-trial adverse effect frequency statements.
Across semaglutide trials, gastrointestinal adverse effects reported included nausea, vomiting, diarrhea, and constipation.
No labeling excerpt provided lists these gastrointestinal adverse effects.
Trials of semaglutide tracked hypoglycemia risk.
No labeling excerpt provided includes hypoglycemia monitoring/tracking statements.
Hypoglycemia risk is generally higher when GLP-1 drugs are used with insulin or insulin secretagogues.
No labeling excerpt provided includes such interaction/relative-risk statements.
Trial programs monitor other serious adverse events.
The excerpt does not specify that trial programs monitor other serious adverse events beyond thyroid C-cell tumors; the statement is too general to confirm from the provided text.
Contradictions
Low
AI Statement
Semaglutide 2.4 mg is marketed as Wegovy.
Label Reference
No contradiction can be assessed because the provided FDA excerpt for OZEMPIC does not address Wegovy marketing; therefore this is categorized as unsupported, not contradicted.
Important Omissions
None of the provided label excerpt includes OZEMPIC dosage, administration instructions, contraindication details beyond MTC/MEN2 and hypersensitivity, or other boxed warning/precautions beyond thyroid C-cell tumor risk. The AI claims include many clinical and dosing/program details that cannot be checked against the supplied excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported safety content provided concerns thyroid C-cell tumor risk and related contraindications/counseling. Most other safety statements (e.g., gastrointestinal frequency, hypoglycemia) are unsupported by the supplied label excerpt; therefore potential risk from misinformation is limited by lack of direct label conflict but still exists due to unsupported details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Most claims reference clinical trial programs, dosing (including 2.4 mg), endpoints, and adverse effect frequencies not present in the provided OZEMPIC FDA label excerpt.
Suggested Improvement
Limit evaluation-supported statements to the provided label content (thyroid C-cell tumor risk, contraindications in MTC/MEN2 and hypersensitivity, uncertainty of human relevance, and counseling/symptom reporting; if discussing other trials/endpoints, provide the corresponding FDA label sections for OZEMPIC).